4D Molecular Therapeutics Inc (FDMT) — Financial Flexibility Index
4D Molecular Therapeutics Inc (FDMT) has a Financial Flexibility Index of 0.48x as of December 2025. Free cash flow of $29.18 Million (operating CF $28.55 Million minus capex $631.00K) represents 0% of total liabilities ($61.05 Million). Also explore how fast is 4D Molecular Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
4D Molecular Therapeutics Inc Financial Flexibility Index (2017–2025)
Historical Financial Flexibility Index trend for 4D Molecular Therapeutics Inc across 9 annual periods. Check FDMT capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for 4D Molecular Therapeutics Inc (2017–2025)
Year-by-year free cash flow to debt coverage for 4D Molecular Therapeutics Inc. For the full company profile including market capitalisation, see FDMT market cap.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.78x | $-108.55 Million | $-109.08 Million | $61.05 Million | ▲ +32.3% |
| 2024 | -2.63x | $-130.80 Million | $-134.59 Million | $49.78 Million | ▼ -15.4% |
| 2023 | -2.28x | $-73.02 Million | $-75.79 Million | $32.06 Million | ▲ +7.5% |
| 2022 | -2.46x | $-75.15 Million | $-86.69 Million | $30.51 Million | ▼ -41.1% |
| 2021 | -1.75x | $-60.02 Million | $-69.13 Million | $34.38 Million | ▼ -11.7% |
| 2020 | -1.56x | $-49.91 Million | $-50.91 Million | $31.94 Million | ▼ -511.8% |
| 2019 | -0.26x | $-33.51 Million | $-36.71 Million | $131.20 Million | ▼ -100.8% |
| 2018 | -0.13x | $-15.84 Million | $-16.25 Million | $124.56 Million | ▼ -167.7% |
| 2017 | 0.19x | $8.81 Million | $8.24 Million | $46.91 Million | — |